Celsus Therapeutics skin cream fails study

(Reuters) – British drugmaker Celsus Therapeutics Plc’s stock plunged as much as 83 percent after the company’s skin cream failed the main goal of a mid-stage study. Celsus chief executive Gur Roshwalb said he was “surprised” by the number of patients who responded to a placebo. The cream, MRX-6, is being developed to treat atopic dermatitis, or eczema, a chronic skin rash or inflammation that often appears in infancy or childhood. The National Institutes of Health (NIH) estimates that eczema affects between 9 and 30 percent of the U.S. population.
Go to Source